questionsmedicales.fr
Maladies de la peau et du tissu conjonctif
Maladies de la peau
Sclérodermie systémique
Sclérodermie diffuse
Sclérodermie diffuse : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Sclérodermie
Diagnostic médical
Signes cliniques
Sclérodermie
Radiographie
Sclérodermie
Symptômes
5
Symptômes respiratoires
Sclérodermie
Atteinte digestive
Sclérodermie
Troubles vasculaires
Sclérodermie
Prévention
5
Facteurs de risque
Sclérodermie
Exposition au froid
Sclérodermie
Traitements
5
Corticostéroïdes
Sclérodermie
Kinésithérapie
Sclérodermie
Traitements expérimentaux
Sclérodermie
Symptômes cutanés
Sclérodermie
Complications
5
Complications
Sclérodermie
Atteintes cardiaques
Sclérodermie
Atteintes rénales
Sclérodermie
Complications digestives
Sclérodermie
Facteurs de risque
5
Facteurs de risque
Sclérodermie
Facteurs environnementaux
Sclérodermie
Maladies auto-immunes
Sclérodermie
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Sclérodermie diffuse : Questions médicales les plus fréquentes",
"headline": "Sclérodermie diffuse : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Sclérodermie diffuse : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-29",
"dateModified": "2025-02-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Sclérodermie diffuse"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Sclérodermie systémique",
"url": "https://questionsmedicales.fr/mesh/D012595",
"about": {
"@type": "MedicalCondition",
"name": "Sclérodermie systémique",
"code": {
"@type": "MedicalCode",
"code": "D012595",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C17.800.784"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Sclérodermie diffuse",
"alternateName": "Scleroderma, Diffuse",
"code": {
"@type": "MedicalCode",
"code": "D045743",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Dinesh Khanna",
"url": "https://questionsmedicales.fr/author/Dinesh%20Khanna",
"affiliation": {
"@type": "Organization",
"name": "Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA."
}
},
{
"@type": "Person",
"name": "Christopher P Denton",
"url": "https://questionsmedicales.fr/author/Christopher%20P%20Denton",
"affiliation": {
"@type": "Organization",
"name": "UCL Division of Medicine, Royal Free Campus, London, UK."
}
},
{
"@type": "Person",
"name": "Ami A Shah",
"url": "https://questionsmedicales.fr/author/Ami%20A%20Shah",
"affiliation": {
"@type": "Organization",
"name": "Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Suite 4100, Baltimore, MD 21224, USA. Electronic address: Ami.Shah@jhmi.edu."
}
},
{
"@type": "Person",
"name": "Susanna Proudman",
"url": "https://questionsmedicales.fr/author/Susanna%20Proudman",
"affiliation": {
"@type": "Organization",
"name": "Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system.",
"datePublished": "2023-04-03",
"url": "https://questionsmedicales.fr/article/37019248",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.neubiorev.2023.105155"
}
},
{
"@type": "ScholarlyArticle",
"name": "Real-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitor Use.",
"datePublished": "2023-05-01",
"url": "https://questionsmedicales.fr/article/36795508",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/FJC.0000000000001404"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessment of serum proprotein convertase subtilisin/kexin type 9 in pediatric sepsis syndrome.",
"datePublished": "2024-07-07",
"url": "https://questionsmedicales.fr/article/38972879",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-65609-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis.",
"datePublished": "2022-07-27",
"url": "https://questionsmedicales.fr/article/35508401",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/heartjnl-2021-320556"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association between proprotein convertase subtilisin/kexin type 9 and subclinical cerebrovascular disease in the community.",
"datePublished": "2023-02-16",
"url": "https://questionsmedicales.fr/article/36727585",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ene.15723"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de la peau et du tissu conjonctif",
"item": "https://questionsmedicales.fr/mesh/D017437"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies de la peau",
"item": "https://questionsmedicales.fr/mesh/D012871"
},
{
"@type": "ListItem",
"position": 4,
"name": "Sclérodermie systémique",
"item": "https://questionsmedicales.fr/mesh/D012595"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sclérodermie diffuse",
"item": "https://questionsmedicales.fr/mesh/D045743"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Sclérodermie diffuse - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Sclérodermie diffuse",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Sclérodermie diffuse",
"description": "Comment diagnostiquer la sclérodermie diffuse ?\nQuels tests sanguins sont utilisés ?\nLes biopsies cutanées sont-elles nécessaires ?\nQuels signes cliniques sont observés ?\nLa radiographie est-elle utile dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Proprotein+Convertase+9#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Sclérodermie diffuse",
"description": "Quels sont les symptômes principaux ?\nLa fatigue est-elle un symptôme courant ?\nY a-t-il des symptômes respiratoires ?\nComment se manifeste l'atteinte digestive ?\nLes troubles vasculaires sont-ils fréquents ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Proprotein+Convertase+9#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Sclérodermie diffuse",
"description": "Peut-on prévenir la sclérodermie diffuse ?\nQuels facteurs de risque sont identifiés ?\nLe tabagisme influence-t-il la maladie ?\nL'exposition au froid est-elle un risque ?\nLes infections peuvent-elles aggraver la maladie ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Proprotein+Convertase+9#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Sclérodermie diffuse",
"description": "Quels traitements sont disponibles ?\nLes corticostéroïdes sont-ils efficaces ?\nQuelles thérapies physiques sont recommandées ?\nY a-t-il des traitements expérimentaux ?\nComment gérer les symptômes cutanés ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Proprotein+Convertase+9#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Sclérodermie diffuse",
"description": "Quelles sont les complications possibles ?\nLa sclérodermie peut-elle affecter le cœur ?\nY a-t-il un risque d'infections ?\nComment la sclérodermie affecte-t-elle les reins ?\nLes complications digestives sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Proprotein+Convertase+9#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Sclérodermie diffuse",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge joue-t-il un rôle ?\nLes facteurs environnementaux sont-ils significatifs ?\nY a-t-il un lien avec d'autres maladies auto-immunes ?\nLe stress peut-il aggraver la maladie ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Proprotein+Convertase+9#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la sclérodermie diffuse ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique, les antécédents médicaux et des tests sanguins."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la recherche d'anticorps spécifiques comme les anticorps anti-Scl-70."
}
},
{
"@type": "Question",
"name": "Les biopsies cutanées sont-elles nécessaires ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être réalisées pour évaluer l'atteinte tissulaire et confirmer le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont observés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent un durcissement de la peau, des œdèmes et des troubles vasculaires."
}
},
{
"@type": "Question",
"name": "La radiographie est-elle utile dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut aider à évaluer les atteintes pulmonaires ou digestives associées."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent un durcissement de la peau, des douleurs articulaires et des troubles digestifs."
}
},
{
"@type": "Question",
"name": "La fatigue est-elle un symptôme courant ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue est fréquente et peut être liée à l'inflammation et à l'atteinte organique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes respiratoires ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des difficultés respiratoires peuvent survenir en raison de l'atteinte pulmonaire."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'atteinte digestive ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se traduire par des reflux, des troubles de la déglutition et des douleurs abdominales."
}
},
{
"@type": "Question",
"name": "Les troubles vasculaires sont-ils fréquents ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des phénomènes de Raynaud et des ulcères digitaux peuvent se produire."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la sclérodermie diffuse ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention connue, mais éviter les facteurs de risque peut aider."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont identifiés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des expositions environnementales et le sexe féminin."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il la maladie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut aggraver les symptômes et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "L'exposition au froid est-elle un risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition au froid peut déclencher des symptômes vasculaires comme le phénomène de Raynaud."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles aggraver la maladie ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent exacerber les symptômes et compliquer la gestion de la maladie."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des immunosuppresseurs, des anti-inflammatoires et des thérapies symptomatiques."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent réduire l'inflammation, mais leur utilisation doit être prudente en raison des effets secondaires."
}
},
{
"@type": "Question",
"name": "Quelles thérapies physiques sont recommandées ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La kinésithérapie peut aider à maintenir la mobilité et à réduire la douleur articulaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements comme les inhibiteurs de la tyrosine kinase sont en cours d'évaluation."
}
},
{
"@type": "Question",
"name": "Comment gérer les symptômes cutanés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des crèmes hydratantes et des traitements topiques peuvent aider à soulager les symptômes cutanés."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des atteintes pulmonaires, cardiaques et rénales, ainsi que des troubles digestifs."
}
},
{
"@type": "Question",
"name": "La sclérodermie peut-elle affecter le cœur ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des arythmies, une hypertension pulmonaire et une insuffisance cardiaque."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque d'infections ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent être plus susceptibles aux infections en raison d'une immunité altérée."
}
},
{
"@type": "Question",
"name": "Comment la sclérodermie affecte-t-elle les reins ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut provoquer une hypertension rénale et une insuffisance rénale, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Les complications digestives sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles incluent des reflux, des troubles de la motilité et des malabsorption."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, le sexe féminin et certaines expositions environnementales sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge joue-t-il un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la sclérodermie diffuse survient généralement entre 30 et 50 ans, mais peut toucher d'autres âges."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux sont-ils significatifs ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des solvants organiques et à la silice peut augmenter le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec d'autres maladies auto-immunes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes ayant d'autres maladies auto-immunes peuvent avoir un risque accru."
}
},
{
"@type": "Question",
"name": "Le stress peut-il aggraver la maladie ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut exacerber les symptômes, bien que son rôle exact dans la sclérodermie ne soit pas clair."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 23/02/2025
Contenu vérifié selon les dernières recommandations médicales
7 publications dans cette catégorie
4 publications dans cette catégorie
Affiliations :
Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Publications dans "Sclérodermie diffuse" :
4 publications dans cette catégorie
Affiliations :
UCL Division of Medicine, Royal Free Campus, London, UK.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Suite 4100, Baltimore, MD 21224, USA. Electronic address: Ami.Shah@jhmi.edu.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Department of Woman's and Child's Health, University of Padua, Via Giustiniani 3, 35128, Padua, Italy. francescozulian58@gmail.com.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Georgetown University Medical Center, Washington (DC), USA.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Lady Davis Institute of the Jewish General Hospital, 4333 Côte-Sainte-Catherine Road,, Montréal, Québec, H3T 1E4, Canada. brett.thombs@mcgill.ca.
Department of Psychology, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Psychiatry, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Medicine, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Educational and Counselling Psychology, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Biomedical Ethics Unit, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
University of Pittsburgh, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Departament of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Departament of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Departament of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine and Rheumatology, Justus-Liebig University Giessen, Giessen, Germany.
Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Suite 4100, Baltimore, MD 21224, USA.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Rheumatology Unit, Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Woman's and Child's Health, University of Padua, Via Giustiniani 3, 35128, Padua, Italy.
Publications dans "Sclérodermie diffuse" :
The gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and its protein product have been widely studied for their role in cholesterol and lipid metabolism. PCSK9 increases the rate of...
Although the proprotein convertase subtilisin kexin-9 inhibitors (PCSK9i) were shown to significantly lower low-density lipoprotein and reduce atherosclerotic cardiovascular disease events in clinical...
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its tissues and organs. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme rel...
To determine the harms of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in people who need lipid-lowering therapy....
This systematic review included randomised controlled trials that compared PCSK9 inhibitors with placebo, standard care or active lipid-lowering comparators in people who need lipid-lowering therapy w...
We included 32 trials with 65 861 participants (with the median follow-up duration of 40 weeks, ranging from 24 to 146 weeks). The meta-analysis showed an incidence of injection-site reaction leading ...
PCSK9 inhibitors slightly increase the risk of severe injection-site reaction but not cataracts, gastrointestinal haemorrhage, neurocognitive events, new-onset diabetes or severe myalgia or muscular p...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new target for reducing low-density lipoprotein cholesterol and incident cardiovascular disease, including stroke. However, the clinical rele...
In community-dwelling Japanese men (n = 526) aged 46-82 years without a history of cardiovascular disease, the associations of serum PCSK9 levels with the prevalence of CSVD and ICAS were assessed usi...
The median (interquartile range) age at baseline and serum PCSK9 levels were 69 (63-74) years and 240 (205-291) ng/ml, respectively. After adjusting for traditional cardiovascular risk factors includi...
Higher circulating PCSK9 levels were independently associated with an ICAS prevalence but not with CSVD prevalence. The quantification of circulating PCSK9 levels may help to identify individuals at h...
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a posttranslational regulator of the LDL receptor (LDLR). Recent studies have proposed a role for PCSK9 in regulating immune responses. Using R...
Guidelines advocate for intensive lipid-lowering in patients with atherosclerotic cardiovascular disease (ASCVD). In May 2020, evolocumab, a proprotein convertase subtilisin-kexin type 9 (PCSK9) inhib...
To identify barriers to prescribing PCSK9 inhibitors in hospitalised patients with ASCVD....
A retrospective 3-month, single-site, observational analysis was conducted in consecutive patients undergoing percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. L...
Of 331 patients, 244 (73.7%) underwent PCI and 87 (26.3%) underwent CABG surgery. A lipid profile during or within 8 weeks of admission was measured for 202 (82.8%) patients undergoing PCI and 59 (67....
Prescribing of non-statin LDL-C-lowering therapies remains low in patients with ASCVD. Underprescribing of ezetimibe and suboptimal lipid testing rates are barriers to accessing subsidised PCSK9i ther...
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) levels have been suggested as novel atherosclerotic biomarker. PCSK9 plays important roles in the pathogenesis of atherosclerosis by regulating th...
This cross-sectional analysis enrolled 401 Caucasian patients with type II diabetes mellitus (T2DM). PCSK9 levels were measured by ELISA test, arterial stiffness was estimated by measuring carotid-fem...
Patients were divided in three tertiles according to increasing value of PCSK9. From the I to the III tertiles, there was a significant increase in high sensitivity C-reactive protein (hs-CRP), fibrin...
Our study demonstrates a close association between circulating PCSK9 levels and PWV in T2DM subjects without previous CV events even after adjusting for well-known CV risk factor and pharmacological m...
Proprotein convertase subtilisin/kexin-type 9 inhibitor (PCSK9i) treatment reduces cardiovascular events when taken over a long time for secondary prevention. Data on treatment adherence are scarce an...
Baseline data and prescription patterns of all 7302 patients with PCSK9i prescriptions dispensed on the account of Austrian Social Insurances between September 2015 and December 2020 were retrieved an...
Considering the high PDC and low discontinuation rates, the majority of patients adhere to PCSK9i treatment. Hence, in a system where PCSK9i treatment is made available at virtually no costs for patie...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces low density lipoprotein (LDL) uptake, leading to increased plasma levels of LDL. In addition, PCSK9 has been implicated in inflammation in...